



**BEYOND MEDICAL
TECHNOLOGIES**

BEYOND MEDICAL TECHNOLOGIES INC.
Suite 915 – 700 West Pender Street
Vancouver, BC V6C 1G8
Canada

***NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE
UNITED STATES***

Beyond Medical Closes Second and Final Tranche of Unit Offering

Vancouver, British Columbia, March 11, 2021 – Beyond Medical Technologies Inc. (“**Beyond Medical**” or the “**Company**”) (CSE: DOCT, Frankfurt: 7FM3) is pleased to announce, further to its news releases dated January 14, 2021, January 20, 2021, and February 5, 2021, it has closed the second and final tranche of the Company’s non-brokered private placement (the “**Private Placement**”) of units (the “**Units**”). In connection with the closing of this final tranche, the Company issued 11,619,500 Units at a price of \$0.125 per Unit for gross proceeds of \$1,452,437.50. Upon the completion of the second and final tranche, the Company has received total gross proceeds of approximately \$2,774,937.50 from the Private Placement.

Each Unit consists of one common share in the capital of the Company (a “**Share**”) and one Share purchase warrant (a “**Warrant**”). Each Warrant is exercisable to purchase one additional Share (a “**Warrant Share**”) at a price of \$0.20 per Warrant Share until March 11th, 2023. The Warrants are subject to an acceleration right of the Company (the “**Warrant Acceleration Right**”) if on any ten (10) consecutive trading days the closing price of the Shares is greater than \$0.40 per Share. If the Company exercises its Warrant Acceleration Right, the new expiry date of the Warrants will be the 30th day following the notice to Warrant holders of such exercise.

All securities issued in connection with the first tranche of the Private Placement are subject to a statutory hold period expiring on July 12, 2021 in accordance with applicable securities legislation. The Company paid aggregate cash finders' fees totalling \$41,746.25 and issued 333,970 finders’ warrants (the “**Finders’ Warrants**”) to certain eligible finders. Each Finders’ Warrant entitles the holder to purchase one Share (a “**Finders’ Warrant Share**”) at an exercise price of \$0.20 per Finders’ Warrant Share until March 11, 2023.

The net proceeds of the Private Placement will be used to fund expenses related to the Company’s previously announced transaction with Kayan Health Limited, to continue to grow the business of its wholly-owned subsidiary Micron Technologies Inc. (“**Micron Technologies**”), to continue the development of the Company’s organic waste digester business, and for general working capital purposes.

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, British Columbia. The Company is developing its Organivore and Pharmavore waste digesters using its proprietary technology. The Company, through its subsidiary Micron Technologies, is also manufacturing medical grade facemasks compliant with ASTM F2100 Standards.

For further information contact:

Kal Malhi, CEO
604-805-4602
kal@bullruncapital.ca

The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold absent registration or compliance with an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

FORWARD LOOKING STATEMENTS:

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.